QUETIAPINE ADD-ON THERAPY MAY IMPROVE PERSISTENT SLEEP DISTURBANCES IN PATIENTS WITH PTSD ON STABILE COMBINED SSRI AND BENZODIAZEPINE COMBINATION: A ONE-GROUP PRETEST-POSTTEST STUDY

To assess potential benefits of quetiapine for persistent sleep disturbances in patients with posttraumatic stress disorder (PTSD) on stable combined SSRI and benzodiazepine therapy, who previously failed to respond to various benzodiazepine and non-benzodiazepine hypnotic adjuvant treatment as well...

Full description

Saved in:
Bibliographic Details
Published inPsychiatria Danubina Vol. 34; no. 2; pp. 245 - 252
Main Authors Vilibic, Maja, Peitl, Vjekoslav, Zivkovic, Maja, Vlatkovic, Suzana, Ljubicic Bistrovic, Ivana, Ljubicic, Rudolf, Matosic, Ana, Karlovic, Dalibor
Format Journal Article
LanguageEnglish
Published 01.07.2022
Online AccessGet full text
ISSN0353-5053
DOI10.24869/psyd.2022.245

Cover

Abstract To assess potential benefits of quetiapine for persistent sleep disturbances in patients with posttraumatic stress disorder (PTSD) on stable combined SSRI and benzodiazepine therapy, who previously failed to respond to various benzodiazepine and non-benzodiazepine hypnotic adjuvant treatment as well as to first-generation antipsychotic add-on treatment.BACKGROUNDTo assess potential benefits of quetiapine for persistent sleep disturbances in patients with posttraumatic stress disorder (PTSD) on stable combined SSRI and benzodiazepine therapy, who previously failed to respond to various benzodiazepine and non-benzodiazepine hypnotic adjuvant treatment as well as to first-generation antipsychotic add-on treatment.Fifty-two male PTSD outpatients on stable combination treatment with SSRI and benzodiazepines, with persistent sleep disturbances not responding to prescription of zolpidem, flurazepam, nitrazepam, promazine, and levopromazine, were assessed for sleep disturbances improvements after prescription of quetiapine in the evening. Each patient met both ICD-10 and DSM-IV criteria for PTSD. Psychiatric comorbidity and premorbidity were excluded using the Mini-International Neuropsychiatric Interview (MINI). Improvement on the CAPS recurrent distressing dream item, reduction in the amount of time needed to fall asleep, prolongation of sleep duration, and reduction in average number of arousals per night in the last 7 days before the assessment period were used as efficacy measures.SUBJECTS AND METHODSFifty-two male PTSD outpatients on stable combination treatment with SSRI and benzodiazepines, with persistent sleep disturbances not responding to prescription of zolpidem, flurazepam, nitrazepam, promazine, and levopromazine, were assessed for sleep disturbances improvements after prescription of quetiapine in the evening. Each patient met both ICD-10 and DSM-IV criteria for PTSD. Psychiatric comorbidity and premorbidity were excluded using the Mini-International Neuropsychiatric Interview (MINI). Improvement on the CAPS recurrent distressing dream item, reduction in the amount of time needed to fall asleep, prolongation of sleep duration, and reduction in average number of arousals per night in the last 7 days before the assessment period were used as efficacy measures.All sleep-related parameters improved significantly at the end of a five-week follow-up: sleep duration increased by one hour (p<0.001), sleep latency decreased by 52.5 minutes (p<0.001), median number of arousals per night decreased from two to one (p<0.001), CAPS recurrent distressing dream item median decreased from five to four (p<0.001), and the number of patients dissatisfied with their sleep quality and quantity decreased from 45 to two (p<0.001).RESULTSAll sleep-related parameters improved significantly at the end of a five-week follow-up: sleep duration increased by one hour (p<0.001), sleep latency decreased by 52.5 minutes (p<0.001), median number of arousals per night decreased from two to one (p<0.001), CAPS recurrent distressing dream item median decreased from five to four (p<0.001), and the number of patients dissatisfied with their sleep quality and quantity decreased from 45 to two (p<0.001).Quetiapine prescribed in the evening may be successful therapy for persistent sleep disturbances in patients with PTSD and generally good response to an SSRI and benzodiazepine combination, who previously failed to respond to some of the usual hypnotic medication or addition of first-generation antipsychotics: zolpidem, flurazepam, nitrazepam, promazine, and levopromazine.CONCLUSIONQuetiapine prescribed in the evening may be successful therapy for persistent sleep disturbances in patients with PTSD and generally good response to an SSRI and benzodiazepine combination, who previously failed to respond to some of the usual hypnotic medication or addition of first-generation antipsychotics: zolpidem, flurazepam, nitrazepam, promazine, and levopromazine.
AbstractList To assess potential benefits of quetiapine for persistent sleep disturbances in patients with posttraumatic stress disorder (PTSD) on stable combined SSRI and benzodiazepine therapy, who previously failed to respond to various benzodiazepine and non-benzodiazepine hypnotic adjuvant treatment as well as to first-generation antipsychotic add-on treatment.BACKGROUNDTo assess potential benefits of quetiapine for persistent sleep disturbances in patients with posttraumatic stress disorder (PTSD) on stable combined SSRI and benzodiazepine therapy, who previously failed to respond to various benzodiazepine and non-benzodiazepine hypnotic adjuvant treatment as well as to first-generation antipsychotic add-on treatment.Fifty-two male PTSD outpatients on stable combination treatment with SSRI and benzodiazepines, with persistent sleep disturbances not responding to prescription of zolpidem, flurazepam, nitrazepam, promazine, and levopromazine, were assessed for sleep disturbances improvements after prescription of quetiapine in the evening. Each patient met both ICD-10 and DSM-IV criteria for PTSD. Psychiatric comorbidity and premorbidity were excluded using the Mini-International Neuropsychiatric Interview (MINI). Improvement on the CAPS recurrent distressing dream item, reduction in the amount of time needed to fall asleep, prolongation of sleep duration, and reduction in average number of arousals per night in the last 7 days before the assessment period were used as efficacy measures.SUBJECTS AND METHODSFifty-two male PTSD outpatients on stable combination treatment with SSRI and benzodiazepines, with persistent sleep disturbances not responding to prescription of zolpidem, flurazepam, nitrazepam, promazine, and levopromazine, were assessed for sleep disturbances improvements after prescription of quetiapine in the evening. Each patient met both ICD-10 and DSM-IV criteria for PTSD. Psychiatric comorbidity and premorbidity were excluded using the Mini-International Neuropsychiatric Interview (MINI). Improvement on the CAPS recurrent distressing dream item, reduction in the amount of time needed to fall asleep, prolongation of sleep duration, and reduction in average number of arousals per night in the last 7 days before the assessment period were used as efficacy measures.All sleep-related parameters improved significantly at the end of a five-week follow-up: sleep duration increased by one hour (p<0.001), sleep latency decreased by 52.5 minutes (p<0.001), median number of arousals per night decreased from two to one (p<0.001), CAPS recurrent distressing dream item median decreased from five to four (p<0.001), and the number of patients dissatisfied with their sleep quality and quantity decreased from 45 to two (p<0.001).RESULTSAll sleep-related parameters improved significantly at the end of a five-week follow-up: sleep duration increased by one hour (p<0.001), sleep latency decreased by 52.5 minutes (p<0.001), median number of arousals per night decreased from two to one (p<0.001), CAPS recurrent distressing dream item median decreased from five to four (p<0.001), and the number of patients dissatisfied with their sleep quality and quantity decreased from 45 to two (p<0.001).Quetiapine prescribed in the evening may be successful therapy for persistent sleep disturbances in patients with PTSD and generally good response to an SSRI and benzodiazepine combination, who previously failed to respond to some of the usual hypnotic medication or addition of first-generation antipsychotics: zolpidem, flurazepam, nitrazepam, promazine, and levopromazine.CONCLUSIONQuetiapine prescribed in the evening may be successful therapy for persistent sleep disturbances in patients with PTSD and generally good response to an SSRI and benzodiazepine combination, who previously failed to respond to some of the usual hypnotic medication or addition of first-generation antipsychotics: zolpidem, flurazepam, nitrazepam, promazine, and levopromazine.
Author Peitl, Vjekoslav
Ljubicic, Rudolf
Ljubicic Bistrovic, Ivana
Vilibic, Maja
Zivkovic, Maja
Matosic, Ana
Karlovic, Dalibor
Vlatkovic, Suzana
Author_xml – sequence: 1
  givenname: Maja
  surname: Vilibic
  fullname: Vilibic, Maja
– sequence: 2
  givenname: Vjekoslav
  surname: Peitl
  fullname: Peitl, Vjekoslav
– sequence: 3
  givenname: Maja
  surname: Zivkovic
  fullname: Zivkovic, Maja
– sequence: 4
  givenname: Suzana
  surname: Vlatkovic
  fullname: Vlatkovic, Suzana
– sequence: 5
  givenname: Ivana
  surname: Ljubicic Bistrovic
  fullname: Ljubicic Bistrovic, Ivana
– sequence: 6
  givenname: Rudolf
  surname: Ljubicic
  fullname: Ljubicic, Rudolf
– sequence: 7
  givenname: Ana
  surname: Matosic
  fullname: Matosic, Ana
– sequence: 8
  givenname: Dalibor
  surname: Karlovic
  fullname: Karlovic, Dalibor
BookMark eNp1kTFv2zAQhTmkQJO0a-Ybs8ilRNKRutEWGxOwJUakWjiLQMkUoMKxHEkZ8sP6_0rHmQJkunu4970b3hW6OPQHh9BNiGcRjefJj-P4uptFOIq8ZhfoEhNGAoYZ-YquxvEvxvMYY3KJ_j2UwkiuZCaAp2mQZ2BWouBqCxu-BblRRf5bgBKFltqIzIBeC6Eg9aosFjxbCg0yA8WN9FcNf6RZgTI6BR-lDV_ItYBlvln4DyloXUjgWQoLkT3mqeSP4u312eAz8uwncI-K4L7ISwWqEEZoE6hcm9PiI8t0-w19ae1-dN_f5zUqfwmzXAXr_F4u-TpoCGVT0LY0tpRR19CQ7gjDrrY1ret5bTGLXYLJ7q6JI2IZxi1lScTadhcnzZ2rSW3biFyj23PuceifX9w4VU_d2Lj93h5c_zJW0TymOEnCMPZWerY2Qz-Og2urppvs1PWHabDdvgpx9dZMdWqmOjXjNfPY7AN2HLonO7x-BvwHetCJPw
CitedBy_id crossref_primary_10_1016_j_neuropharm_2022_109211
crossref_primary_10_1016_j_heliyon_2024_e33993
crossref_primary_10_1080_03007995_2024_2308016
ContentType Journal Article
CorporateAuthor Department of Psychiatry, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Department for Psychotic Disorders, University Psychiatric Hospital Vrapče, Zagreb, Croatia
Department of Psychiatry, Clinical Hospital Centre of Rijeka, Rijeka, Croatia
School of Medicine, University of Zagreb, Zagreb,Croatia
School of Medicine, University of Rijeka, Rijeka, Croatia
School of Medicine, Catholic University of Croatia, Zagreb, Croatia
CorporateAuthor_xml – name: Department of Psychiatry, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
– name: Department of Psychiatry, Clinical Hospital Centre of Rijeka, Rijeka, Croatia
– name: School of Medicine, University of Zagreb, Zagreb,Croatia
– name: Department for Psychotic Disorders, University Psychiatric Hospital Vrapče, Zagreb, Croatia
– name: School of Medicine, University of Rijeka, Rijeka, Croatia
– name: School of Medicine, Catholic University of Croatia, Zagreb, Croatia
– name: Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
– name: School of Dental Medicine, University of Zagreb, Zagreb, Croatia
DBID AAYXX
CITATION
7X8
DOI 10.24869/psyd.2022.245
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 252
ExternalDocumentID 10_24869_psyd_2022_245
GroupedDBID ---
123
AAFWJ
AAYXX
ABIVO
ACHQT
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CITATION
DIK
EBD
EMOBN
EOJEC
F5P
OBODZ
OK1
SV3
VP8
7X8
ID FETCH-LOGICAL-c345t-ff48a454ec414d350ebab4bb6ba058e903d7c823a500f45925ffd89c7eb3baf23
ISSN 0353-5053
IngestDate Fri Jul 11 16:02:38 EDT 2025
Thu Apr 24 23:05:32 EDT 2025
Tue Jul 01 02:40:54 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c345t-ff48a454ec414d350ebab4bb6ba058e903d7c823a500f45925ffd89c7eb3baf23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.24869/psyd.2022.245
PQID 2684099118
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_2684099118
crossref_citationtrail_10_24869_psyd_2022_245
crossref_primary_10_24869_psyd_2022_245
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20220701
PublicationDateYYYYMMDD 2022-07-01
PublicationDate_xml – month: 07
  year: 2022
  text: 20220701
  day: 01
PublicationDecade 2020
PublicationTitle Psychiatria Danubina
PublicationYear 2022
SSID ssj0068003
Score 2.2776759
Snippet To assess potential benefits of quetiapine for persistent sleep disturbances in patients with posttraumatic stress disorder (PTSD) on stable combined SSRI and...
SourceID proquest
crossref
SourceType Aggregation Database
Enrichment Source
Index Database
StartPage 245
Title QUETIAPINE ADD-ON THERAPY MAY IMPROVE PERSISTENT SLEEP DISTURBANCES IN PATIENTS WITH PTSD ON STABILE COMBINED SSRI AND BENZODIAZEPINE COMBINATION: A ONE-GROUP PRETEST-POSTTEST STUDY
URI https://www.proquest.com/docview/2684099118
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  issn: 0353-5053
  databaseCode: DIK
  dateStart: 20080101
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: http://www.freemedicaljournals.com
  omitProxy: true
  ssIdentifier: ssj0068003
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKkBAviJ9i_NIhMXioPNrETlPeunXTBttaaIf6FsWJI3WrkjKSSvT_4v_jznHaZmLS4CVKk0td9b6cP9vn7xh7pyJPYccf8Qj7Dy7cjuZ-ohV3fB0aBu2V2RZn3tG5-DyRk0ZjUyG4yNVutPzrvpL_8SpeQ7_SLtl_8OzqS_ECnqN_8YgexuOtfPy10PiCzoko9uKYD1JKoCCRgOZp-KtZzhdok-ROzkzz5mim9ZwUN7GjUeRvkw07LLVV7Ua34XjUpyUEpKEKQwZFDBw9Ey8dfTs2aw17Ol1miKulNk2XBqsskV5zkGpuJ7muaF4351QSmE5M2mJtIXlYZVtPQ0JgoWw5b1MEjLR_p4budsp9RRfhOpTj4yZJ90JfZojrRXVnZ1_u7PWni8tsccOz32dhXr87KpahbdfOgDjrbNnVzi_pcmRy7mZUt1Ok043BtQ3RpXzl9a7DEb5H0qtzkjmgVnatYV2j-2wQHJ6fnATjg8n4_fwHp_JltMxva7ncYXedjudRKY3-8ZeKEnjIyss63faHluqhpsmPtQbr7KhODgzjGT9kD-xQBXol7h6xhk4fs3unNhnjCfu9hh-U8AMLP0D4gYUfrOEHBn6wCT-YplDBDwh-QPCDLAULP6jgBwQ_QPhBHX6wAb9P0IMV-OA6-MCA7yk7PzwY7x9xWwWER66QOU8S4YdCCh2Jtohd2dIqVEIpT4Ut6etuy407ke-4VNojEbLryCSJ_W7U0cpVYeK4z9hWmqX6OYNYeD6OEFqqrZRAHt0VQgsVyThBHt_uym3Gq38_iKxEPlVqmQU4VDbeCshbAXkLP6P9h5X9vBSHudHybeXMAOM3LcqFqc6Kn4FRW8JBWtt_cQubl-z--g14xbbyq0K_RlacqzcGcX8AflC_HA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quetiapine+Add-On+Therapy+May+Improve+Persistent+Sleep+Disturbances+in+Patients+with+PTSD+on+Stabile+Combined+SSRI+and+Benzodiazepine+Combination%3A+A+One-Group+Pretest-Posttest+Study&rft.jtitle=Psychiatria+Danubina&rft.au=Vilibi%C4%87%2C+Maja&rft.au=Peitl%2C+Vjekoslav&rft.au=%C5%BDivkovi%C4%87%2C+Maja&rft.au=Vlatkovi%C4%87%2C+Suzana&rft.date=2022-07-01&rft.issn=0353-5053&rft.volume=34&rft.issue=2&rft.spage=245&rft_id=info:doi/10.24869%2Fpsyd.2022.245&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0353-5053&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0353-5053&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0353-5053&client=summon